Low-pass Filtering SpeechNCT05435989
Extended High-frequency Hearing and Speech Perception
A study testing Reduced extended high-frequency audibility in people with Low-pass Filtering Speech, run by Brian Monson at 1 site in United States.
Trial summary
This study examines the effects of low-pass filtering speech on speech perception. Read more about this study
- Who is it for?
- Ages 19 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Low-pass Filtering Speech
- What is being tested?
- Reduced extended high-frequency audibility
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 480 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Nov 2021to Jun 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- native speakers of American English
- normal hearing 250-8000 Hz
Who cannot join
- non-native speakers of American English
- hearing loss
Trial locations and contacts
1 site in 1 country.
United States1 site, 1 recruiting
- Recruiting
University of Illinois Urbana-Champaign
Champaign, Illinois, 61820
Brian Monson, PhD, 217-300-6212, monson@illinois.edu
About this study
This study examines the effects of low-pass filtering speech on speech perception.
- Conditions
- Low-pass Filtering Speech
- Being tested
- Reduced extended high-frequency audibility
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Reduced extended high-frequency audibilityDiagnostic test
This study examines the effects of low-pass filtering speech on speech perception.
| Study group | Role | What they receive |
|---|---|---|
| Normal-hearing listeners | Experimental | Not described Receives: Diagnostic Test: Reduced extended high-frequency audibility |
What is being measured
The primary outcome is the main question the study is designed to answer.
Speech recognition or localization score
Speech recognition or localization scores are assessed using alternative forced choice procedures implemented with custom software scripts (e.g. in Matlab)
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jun 2022
- Study start9 Nov 2021
- Primary completionJun 2026 (estimated)
- Study completionJun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Low-pass Filtering SpeechStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 480 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Brian Monson
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Deafness and Other Communication Disorders (NIDCD)
- Responsible party
- Sponsor-investigator, Brian Monson, University of Illinois at Urbana-Champaign
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05435989
- Sponsor's protocol ID
- AH181
- Other IDs
- R01DC019745
- Status last verified
- May 2023
- First submitted
- 16 Jun 2022
- Last updated
- 10 May 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 10 May 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Extended High-frequency Hearing and Speech Perception
- ClinicalTrials.gov ID
- NCT05435989
- Acronym / sponsor ID
- AH181
- Conditions
- Low-pass Filtering Speech
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 480 participants (estimated)
- Lead sponsor
- Brian MonsonUniversity, hospital or other
- Collaborators
- National Institute on Deafness and Other Communication Disorders (NIDCD)
- Study start
- 9 Nov 2021 (actual)
- Primary completion
- Jun 2026 (estimated)
- Study completion
- Jun 2026 (estimated)
- First posted
- 28 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study examines the effects of low-pass filtering speech on speech perception.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Normal-hearing listeners | Experimental | Diagnostic Test: Reduced extended high-frequency audibility |
Who may qualify
- Ages
- 19 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- native speakers of American English
- normal hearing 250-8000 Hz
Key exclusion criteria (2 listed)
- non-native speakers of American English
- hearing loss
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Reduced extended high-frequency audibilityThis study examines the effects of low-pass filtering speech on speech perception. | Diagnostic test | Normal-hearing listeners |
Primary outcome
Speech recognition or localization score
Time frame: Day 1
Speech recognition or localization scores are assessed using alternative forced choice procedures implemented with custom software scripts (e.g. in Matlab)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 May 2023.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Reduced extended high-frequency audibility in people with Low-pass Filtering Speech, run by Brian Monson at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 10 May 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Brian Monson, PhD (217-300-6212, monson@illinois.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Speech recognition or localization score (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 May 2023.